Dr. Akshay Jain has actively participated as the local site primary investigator for the following Clinical Phase III/ IV studies using novel medications/devices for treatment of diabetes, obesity, cardiovascular disease and elevated cholesterol.

• PIONEER REAL: Real world outcome study with oral semaglutide (National PI)
• PREFER CA: Real world outcome study with flash glucose monitoring in basal insulin
• SPOT FIRST: Real world outcome with flash glucose monitoring prior to specialist appointment
• SURE: Real world outcome study with Semaglutide
• REALISE-DM: Real world outcome on switching from liraglutide/dulaglutide to semaglutide
• GLITTER: Real world outcome using retrospective flash glucose monitoring
• DECLARE- TIMI: MACE outcome study with Dapagliflozin
• CAMELLIA: MACE outcome study with Lorcaserin
• SERTUS: Active comparator efficacy study with Ertugliflozin
• CANNON: Albuminuria study with Canagliflozin in DM-1
• REWIND: MACE outcome study with Dulaglutide
• SPIRE 1 &2: Cardiovascular outcome study with Bococizumab
• LEXICON: Insulin dose outcome study with Sotagliflozin in DM-1
• EASE-2: Safety and Tolerability study with Empagliflozin in DM-1
• CANCARE: Prospective registry database study with Canagliflozin
• ONSET 8: Randomized controlled trial with insulin Degludec and Faster acting Insulin Aspart in DM-1
• GOAL RCT: Randomized controlled trial comparing effect of colesevelam versus ezetimibe as add-on to HMG CoA Reductase inhibitor therapy in DM-2

 

HCF